Obsidian Therapeutics (NASDAQ:OBX) Receives $42.50 Consensus Price Target from Analysts

Shares of Obsidian Therapeutics (NASDAQ:OBX) have received an average rating of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $42.50.

A number of equities analysts have recently weighed in on OBX shares. William Blair began coverage on shares of Obsidian Therapeutics in a research report on Wednesday, September 9th. They issued an “outperform” rating for the company. Zacks Research upgraded Obsidian Therapeutics to a “hold” rating in a report on Thursday, August 6th. Piper Sandler initiated coverage on Obsidian Therapeutics in a research note on Wednesday, August 5th. They set an “overweight” rating and a $42.00 price target on the stock. Weiss Ratings assumed coverage on Obsidian Therapeutics in a report on Wednesday, September 2nd. They set a “sell (d-)” rating on the stock. Finally, TD Cowen began coverage on Obsidian Therapeutics in a research report on Thursday, August 6th. They issued a “buy” rating for the company.

Obsidian Therapeutics Stock Down 6.1%

NASDAQ:OBX opened at $17.00 on Wednesday. Obsidian Therapeutics has a 12-month low of $14.57 and a 12-month high of $49.97.

About Obsidian Therapeutics

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.